Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) - Pipeline Review, H1 2016

  • ID: 3788881
  • Report
  • 72 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • Akshaya Bio Inc.
  • Boehringer Ingelheim GmbH
  • Etubics Corporation
  • Merck KGaA
  • Transgene SA
  • MORE
Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) - Pipeline Review, H1 2016

Summary

‘Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) - Pipeline Review, H1 2016’, provides in depth analysis on Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) targeted pipeline therapeutics.

The report provides comprehensive information on the Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227)
- The report reviews Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) targeted therapeutics and enlists all their major and minor projects
- The report assesses Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Akshaya Bio Inc.
  • Boehringer Ingelheim GmbH
  • Etubics Corporation
  • Merck KGaA
  • Transgene SA
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) Overview

Therapeutics Development

Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) - Products under Development by Stage of Development

Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) - Products under Development by Therapy Area

Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) - Products under Development by Indication

Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) - Products under Development by Companies

Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) - Products under Development by Universities/Institutes

Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) - Companies Involved in Therapeutics Development

Akshaya Bio Inc.

Boehringer Ingelheim GmbH

Etubics Corporation

Merck KGaA

Minerva Biotechnologies Corporation

Transgene SA

Vaxil Bio Therapeutics Ltd.

Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) - Drug Profiles

BI-1361849 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GO-2032c - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ImMucin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit MUC1 for Solid Tumors - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tecemotide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TG-4010 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine 1 to Target MUC-1 Protein for Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine 2 to Target MUC-1 Protein for Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine 3 to Target MUC-1 Protein for Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target MUC-1 and TLR-2 for Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target MUC1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target MUC1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target MUC1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target MUC1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target MUC1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) - Dormant Projects

Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) - Discontinued Products

Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) - Featured News & Press Releases

Mar 31, 2016: Vaxil Receives Canadian Notice of Patent Allowance for Its Lead Immunotherapy Platform, Including Its ImMucin Cancer Vaccine

Dec 23, 2015: Transgene Announces Publication in “The Lancet Oncology” of Phase 2b TIME Trial Results with TG4010 Immunotherapy in Non-Small Cell Lung Cancer

Sep 08, 2015: Transgene Announces Final Overall Survival Data from Phase 2b TIME Trial with TG4010 Immunotherapy in Non-Small Cell Lung Cancer

Aug 19, 2015: Transgene Announces Oral Presentation on TG4010 Cancer Immunotherapy at World Conference on Lung Cancer

Jun 22, 2015: Vaxil's Lead Product ImMucin has Been Granted an Orphan Drug Designation by the FDA for the Treatment of Multiple Myeloma

Jun 01, 2015: Transgene Announces Positive New Results Presented at ASCO from Phase 2b TIME Trial with TG4010 Immunotherapy in Non-Small Cell Lung Cancer

Apr 21, 2015: Transgene Presents New Pre-Clinical Data at AACR on the Combination of TG4010 with Immune Checkpoint Inhibitors

Mar 16, 2015: VAXIL Receives EU Orphan Drug Designation for ImMucin for the Treatment of Multiple Myeloma

Jan 21, 2015: NCCS Conducts World’s First-In-Human Clinical Trial Of A Novel Cancer Vaccine Targeting Top Cancers In Singapore

Dec 15, 2014: Vaxil publishes the results of its Phase I/II study using ImMucin in Myeloma Patients in the "British Journal of Hematology"

Nov 09, 2014: Vaxil has published a review article describing key advantages for its VaxHit technology

Sep 29, 2014: Transgene Presents Additional Positive Clinical Data from Phase 2b Part of TIME Trial with TG4010 at ESMO

Sep 12, 2014: Merck Discontinues Clinical Development Program of Tecemotide as a Monotherapy in Stage III Non - Small Cell Lung Cancer

Aug 18, 2014: Merck Announces Clinical Failure Of Tecemotide Cancer Vaccine

Aug 12, 2014: MicroVAX Cancer Vaccine First in Human Clinical Trial in Singapore

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 72List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Akshaya Bio Inc., H1 2016

Pipeline by Boehringer Ingelheim GmbH, H1 2016

Pipeline by Etubics Corporation, H1 2016

Pipeline by Merck KGaA, H1 2016

Pipeline by Minerva Biotechnologies Corporation, H1 2016

Pipeline by Transgene SA, H1 2016

Pipeline by Vaxil Bio Therapeutics Ltd., H1 2016

Dormant Projects, H1 2016

Discontinued Products, H1 2016 60List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Akshaya Bio Inc.
  • Boehringer Ingelheim GmbH
  • Etubics Corporation
  • Merck KGaA
  • Transgene SA
  • MORE
Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) pipeline Target constitutes close to 17 molecules. Out of which approximately 10 molecules are developed by Companies and remaining by the Universities/Institutes. Our latest report Mucin 1 – Pipeline Review, H1 2016, outlays comprehensive information on the Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) Mucin 1, cell surface associated (MUC1) or polymorphic epithelial mucin (PEM) is a mucin encoded by the MUC1 gene. It acts both as an adhesion and an anti-adhesion protein. It provides a protective layer on epithelial cells against bacterial and enzyme attack. It is involved in cell signaling through phosphorylations and protein-protein interactions. It modulates signaling in ERK, SRC and NF-kappa-B pathways. It promotes tumor progression. It regulates TP53-mediated transcription and determines cell fate in the genotoxic stress response. The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 1, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 5 and 1 molecules, respectively.

Furthermore, this report also reviews key players involved in Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Driven by data built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
Akshaya Bio Inc.
Boehringer Ingelheim GmbH
Etubics Corporation
Merck KGaA
Minerva Biotechnologies Corporation
Transgene SA
Vaxil Bio Therapeutics Ltd.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll